Impact of In-Hospital Revascularization on Survival in Patients With Non–ST-Elevation Acute Coronary Syndrome and Congestive Heart Failure Philippe Gabriel.

Slides:



Advertisements
Similar presentations
1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.
Advertisements

CHEST PAIN Belgian Inter disciplinary Working group of Acute Cardiology Claeys MJ Vandekerckhove Y Bossaert L Calle P Martens P Hollanders G Vrints C Van.
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
Current and Future Perspectives on Acute Coronary Syndromes Paul W. Armstrong MD AMI Quebec Montreal October 1, 2010.
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Impact of Prior Peripheral Arterial Disease and Stroke on Outcomes of Acute Coronary Syndromes and Effect of Evidence-Based Therapies (from the Global.
Heart Failure Whistle Stop Talks No. 2 Classification Implications Susie Bowell BA Hons, RGN Heart Failure Specialist Nurse.
Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
Exercise Echocardiography Cardiac Issues 2011 Douglass A Morrison, MD, PhD.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
1 What is… ? Disparities Among Women in Acute Cardiac Care Frances Canet, MD Cath Conference Thursday, May 26, 2011.
ATLAS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
Amr Hassan Mostafa, MD, FSCAI A. Professor of Cardiology Cairo University Cairo, Egypt Egypt Combat MI, March 24-25, Cairo Sheraton.
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
ACUTE CORONARY SYNDROME (ACS). ACS Pathophysiology is that of a ruptured or eroded atheromatous plaque. Pathophysiology is that of a ruptured or eroded.
EKGs in pre-operative management for OSH transfers.
Number Needed to Treat. End Points Baseline Risk is the risk associated with a particular condition Baseline Risk is the risk associated with a particular.
Absence of Flow-Limiting Coronary Artery Disease Among Patients Undergoing Emergent Cardiac Catheterization For ST Segment Elevation Myocardial Infarction.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Author: Moldovan Carmen Co-authors: Opincariu Diana Balan Daniel University of Medicine and Pharmacy Tg. Mures Cardiology Clinic, Mures Emergency Clinical.
Silent Ischemia STABLE CAD
Farrokh Alemi, Ph.D..  Compare effectiveness  Low dose rofecoxib (Vioxx)  High dose rofecoxib (Vioxx)  Celecoxib  Other medication.
Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial.
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
Impact of Drug-Eluting Stents on Revascularization Choices in Patients with Acute Coronary Syndromes and Multivessel Coronary Disease: Results from the.
ACUTE CORONARY SYNDORME Mostafa alshamiri January 2013.
Does early beta-blockade decrease mortality in STEMI?
Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.
Coronary Heart Disease (CHD) László Tornóci Inst. Pathophysiology Semmelweis University.
Acute Coronary Syndromes Risk-Stratification Pathophysiology Diagnosis Initial Therapy Risk-Stratification Risk-Stratification Invasive vs Conservative.
Late Open Artery Hypothesis Jason S. Finkelstein, M.D. Tulane University Medical Center 2/24/03.
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.
Annual Patient Admissions for Acute Coronary Syndromes 1.4 MM Non-ST elevation ACS 0.6 MM ST-elevation MI ~ 2.0 MM patients admitted to CCU or telemetry.
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Omega-3 Polyunsaturated Fatty Acids and Cardiovascular.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
A pilot randomized controlled trial Registry #: NCT
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.
Figure 9.1 Causes of death in ESRD patients,
Prognosis of Patients With LV Dysfunction and CAD
Arch Intern Med. 2007;167(1): doi: /archinte Figure Legend:
Improving Outcomes in Cardiogenic Shock
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
Patient populations by study group figure 10
Cost Effective Use of Troponin to Rule Out Acute Coronary Syndrome
Bayard R. Wilson, BA, Kathryn R. Tringale, BS, Brian R
Jeff Macemon Waikato Cardiothoracic Unit
European Heart Association Journal 2007 April
Quantitating the Dose of Physical Activity in Secondary Prevention: Relation of Exercise Intensity to Survival  Barry A. Franklin, PhD  Mayo Clinic Proceedings 
Exercise-Based Cardiac Rehabilitation and Improvements in Cardiorespiratory Fitness: Implications Regarding Patient Benefit  Barry A. Franklin, PhD  Mayo.
Risk Stratification in Non-ST-segment Elevation Acute Coronary Syndromes: Troponin Alone Is not Enough  Philippe Gabriel Steg, Gordon FitzGerald, Keith.
Global Registry of Acute Coronary Events: GRACE
Institute of Cardiology
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
Long-Term Survival After Coronary Arterial Grafts in Patients With End-Stage Renal Disease  Taro Nakatsu, MD, Nobushige Tamura, MD, PhD, Yutaka Sakakibara,
Recent Temporal Changes in Atherosclerotic Cardiovascular Diseases in Ontario: Clinical and Health Systems Impact  Jack V. Tu, MD, PhD, Anam M. Khan,
Comparison of radial versus femoral access in patients undergoing invasive management for acute coronary syndromes: evidence from a systematic review and.
China Patient‑centered Evaluative Assessment of Cardiac Events Prospective Study of Acute Myocardial Infarction: Study Design Jing Li, Rachel P Dreyer,
Total Arterial Off-Pump Coronary Surgery: Time to Change Our Habits?
Cardiovascular Epidemiology and Epidemiological Modelling
Figure 9.1.a Causes of death in ESRD patients,
Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.
Presentation transcript:

Impact of In-Hospital Revascularization on Survival in Patients With Non–ST-Elevation Acute Coronary Syndrome and Congestive Heart Failure Philippe Gabriel Steg, MD; Arthur Kerner, MD; Frans Van de Werf, MD, PhD; José López-Sendón, MD; Joel M. Gore, MD; Gordon FitzGerald, PhD; Laurent J. Feldman, MD, PhD; Frederick A. Anderson, PhD; Álvaro Avezum, MD, PhD; Circulation 2008;118; R3. 조병현

Page  2  CHF  Common in patients with an acute coronary syndrome  Reports from the GRACE  Pt with AMI : 20%  Pt with UA : 10%  ACS+CHF  Poor prognosis  Guidelines  High risk NSTE-ACS : early CAG&PCI  GRACE : less likely undergo intervention or medication Background 1. Describe the use of revascularization in patients with NSTE-ACS with and without CHF. 2. Analyze the impact of early revascularization on survival in those with CHF.

Page  3  CHF  Killip class I : Includes individuals with no clinical signs of heart failure II : Includes individuals with rales or crackles in the lungs, an S3 gallop, and elevated jugular venous pressure III : Describes individuals with frank acute pulmonary edema IV : Describes individuals in cardiogenic shock or hypotension Background

Page  4 Patients Patients enrolled in GRACE >=18 years Clinical history of ACS At least one of followings ECG changes consistent with ACS Increase in cardiac markers Coronary artery disease Method

Page  5 Patients Excluded With noncardiovascular causes for the clinical presentation Missing CHF status Cardiogenic shock Transferred from another hospital The revascularization status, date, or other covariates were missing CHF during hospitalization Method

Page  6 Method

Page  7 RESULTS

Page  8 RESULTS

Page  9 Result

Page  10 RESULTS

Page  11 RESULTS

Page  12 RESULTS

Page  13 RESULTS

Page  14 RESULTS

Page  15 RESULTS

Page  16 RESULTS

Page  17 Discussion  If suitable for revascularization –Patients not suitable for procedure due to reasons like comorbidities were excluded  SHOCK trial –Similar result No reduction on overall rate of death at 30days After 6 months, significant survival benefit  Negative interaction with sex –Need for further study regarding the role of revascularization in women with high-risk ACS

Page  18 Discussion  Mechanisms for benefit of revascularization –Receive more 2ndary prevention drugs –Reduction in the size of infarction –Salvage of myocardium –Attenuation of remodeling –Prevention of further cardiovascular events

Page  19  Strength and limitation –GRACE is largest multinational registry –Include complete spectrum of patients with ACS –Potential biases –The selection of low-risk patients –Due to exclusion of patients who developed heart failure after admission Discussion

Page  20 Conclusion  The use of revascularization in NSTE-ACS patients with CHF is low.  It is associated with a significant post-discharge survival benefit.  Broader use of revascularization in these patients may save lives.